Search

Call for interest

As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.

Read more

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

Sponsors

If you want to go fast, go alone. If you want to go far, go together. We aim for long-term relationships with our partners and sponsors.

Read more

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

Research Committee call for interest

The overarching aim of the Research Committee is to further strengthen EHA’s interactions with and relevance for the wider hematological research community.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more